Joe Rogan Experience #2566 - Cody Tucker · Aired Oct 15, 2026
Claim summary · not a verbatim quotation
Joe Rogan says pharmaceutical studies have no transparency and peer reviewers cannot inspect the actual underlying data.
The finding
What the evidence shows
Part of this is accurate. A former FDA reviewer notes that journal peer reviewers typically see only the summary statistics the authors or sponsors give them, not the raw data. But 'no transparency' goes too far. The same source says FDA statisticians do get the raw data from the sponsor and check whether the findings hold up. They also compare the results with the original study plan. A check that would flip this verdict is evidence that journal reviewers routinely receive full trial datasets, or that the FDA does not receive them.
Read the supporting source · www.ncbi.nlm.nih.gov ↗Quick answer & review status
Quick answer
Is it true that Joe Rogan says pharmaceutical studies have no transparency and peer reviewers cannot inspect the actual underlying data?
It leaves out the other side. Part of this is accurate. A former FDA reviewer notes that journal peer reviewers typically see only the summary statistics the authors or sponsors give them, not the raw data. Joe Rogan said it (matched by voice) on Joe Rogan Experience #2566 - Cody Tucker, aired Oct 15, 2026, at 9:52. The supporting source is ncbi.nlm.nih.gov, linked below.
The context belongs here.
No separately verified on-air correction is recorded for this check. That is not a claim that nobody corrected it.
- Attribution
- Not independently confirmed in this record
- Editorial context review
- Not recorded; generated finding
- Coverage
- One selected claim from the episode
Revisions to this check
No dated revision is recorded here. Older checks may predate this log.
Challenge this finding or add context →Keep the evidence coming.
Follow new checks in your RSS reader, or catch up with the weekly briefing on the site.
Email signup is currently unavailable.
Prefer to catch up here? Read the weekly briefing.